Denifanstat Trial Results Showed Significant Acne Reduction
The oral fatty acid synthase inhibitor demonstrated long-term efficacy in a 52-week clinical study.
Updated on Oct. 10, 2026 in Biotech
Live Poll
Should pharmaceutical companies accelerate the development of new oral medications for moderate to severe acne?
Sagimet Biosciences presented 52-week clinical trial results for denifanstat, showing significant skin improvement in patients with moderate to severe acne vulgaris. The results stem from an open-label extension trial conducted in China.
Why it matters
The development marks a shift in acne treatment by targeting fatty acid synthesis rather than traditional hormonal or antibiotic pathways. This approach represents a potential new therapeutic category for chronic inflammatory skin conditions.
In a study of 240 patients, a 50 mg daily dose of the oral small molecule denifanstat achieved a 57% IGA success rate and a 77% reduction in inflammatory lesions. These figures track performance against baseline metrics for moderate to severe acne.
The players
Sagimet Biosciences
A biotechnology company focused on developing FASN inhibitors to treat metabolic and dermatological diseases.
Ascletis BioScience Co. Ltd.
A biopharmaceutical company that managed the Phase 3 clinical trials for denifanstat in China.
The details
Denifanstat functions as a fatty acid synthase (FASN) inhibitor, a molecule that blocks an enzyme responsible for synthesizing fatty acids that contribute to skin sebum production. By inhibiting FASN, the drug targets the underlying biological mechanisms of acne pathogenesis. The trial utilized an open-label extension—a study where all participants receive the treatment—to track long-term safety and efficacy following a 12-week double-blind study.
Timeline
In December 2025, the Chinese NMPA accepted the NDA for denifanstat.
From October 8-11, 2026, results were presented at the Fall Clinical Dermatology Conference.
In October 2026, patient screening began for the U.S. AURORA Phase 3 trial.
The Tech Race
The data from the Chinese trials provides the foundation for the upcoming U.S. AURORA Phase 3 clinical program. This effort is designed to validate the efficacy of denifanstat in a larger population, specifically targeting 800 patients including 450 adolescents.
Denifanstat is not yet available for prescription as it remains in the clinical trial phase in the United States. Patients and providers should monitor the progress of the AURORA trial to determine the potential timeline for market entry.
The takeaway
The sustained success of denifanstat in reducing inflammatory lesions highlights the potential of FASN inhibitors in dermatology. Future updates regarding the U.S. AURORA trial results will confirm whether this treatment offers a viable alternative to current standard-of-care therapies.
Further reading
Explore more developments in pharmaceutical research on our Biotech section.
Live Poll
Should pharmaceutical companies accelerate the development of new oral medications for moderate to severe acne?
